skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Talimogene Laherparepvec (Code C61314)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Talimogene Laherparepvec

Definition: An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.

Display Name: Talimogene Laherparepvec

Label: Talimogene Laherparepvec

NCI Thesaurus Code: C61314 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831828  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene
JS1 34.5-hGMCSF 47- pA-
Talimogene Laherparepvec

External Source Codes: 
CAS Registry Number 1187560-31-1 (see NLM ChemIDplus info)
FDA UNII Code 07730V90L6
PDQ Closed Trial Search ID 485296
PDQ Open Trial Search ID 485296 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831828

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
code C61314
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name GM-CSF-Encoding_Oncolytic_Herpes_Simplex_Virus_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom